News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Stephen V Liu Shared NEOADAURA Results Published in JCO After ASCO25 Presentation
Stephen V Liu/X
Jun 8, 2025, 06:08

Stephen V Liu Shared NEOADAURA Results Published in JCO After ASCO25 Presentation

Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:

“NEOADAURA results published in JCO after ASCO 2025 presentation.
In patients with resectable EGFR-Mutated NSCLC, neoadjuvant osimertinib for 9 weeks led to MPR rate of 25%, osimertinib + chemotherapy MPR 26%, and placebo + chemotherapy MPR of 2%. EFS rates high, but most patients received adjuvant osimertinib.”

Title: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer

Journal: Journal of Clinical Oncology

Authors: Jianxing He, Masahiro Tsuboi, Walter Weder, Ke-Neng Chen, Maximilian J. Hochmair, Jin-Yuan Shih, Sung Yong Lee, Kang-Yun Lee, Nguyen Viet Nhung, Somcharoen Saeteng, Lunxu Liu, Ligang Xing, Nguyen Hoang Gia, Shuji Murakami, Yongtao Han, María Paz Saavedra, Seong Hoon Yoon, Carlos H.A. Teixeira, Carles Escriu, Alex Martinez-Marti, Collin M. Blakely, Yasushi Yatabe, Sanja Dacic, Yuri Rukazenkov, Xiangning Huang, Anupriya Dayal, Jamie E. Chaft

Read the full abstract.

NEOADAURA

More posts featuring Stephen V Liu on OncoDaily.

Alex Martínez-Martí Anupriya Dayal ASCO ASCO 2025 ASCO25 cancer Carles Escriu Carlos H.A. Teixeira Collin M. Blakely EGFR-mutant NSCLC Georgetown University Jamie E Chaft JCO Jianxing He Jin-Yuan Shih Kang-Yun Lee Ke-Neng Chen Ligang Xing Lunxu Liu María Paz Saavedra Masahiro Tsuboi Maximilian J. Hochmair NeoADAURA Nguyen Hoang Gia Nguyen Viet Nhung OncoDaily Oncology Sanja Dacic Seong Hoon Yoon Shuji Murakami Somcharoen Saeteng Stephen V Liu Sung Yong Lee Walter Weder Xiangning Huang Yasushi Yatabe Yongtao Han Yuri Rukazenkov
Special Coverage
Insight
Jun 8, 2025, 06:08
Stephen V Liu Shared NEOADAURA Results Published in JCO After ASCO25 Presentation
Insight
Jun 8, 2025, 06:06
Martin Makary Shared Insights from FDA Cell and Gene Therapy Roundtable
Societies
Jun 8, 2025, 06:04
Common Sense Oncology to Host ASCO 2025 Recap Webinar on June 19
Blog
Jun 8, 2025, 06:02
Ghassan Abou-Alfa Congratulated Layal Al Mahmasani on Graduation from Memorial Sloan Kettering Cancer Center
Insight
Jun 8, 2025, 05:59
Douglas Flora Shared Insights on AI’s Role in Oncology on AI in Precision Oncology
Insight
Jun 8, 2025, 05:57
SWOG's Pragmatica-Lung Study as Model for Patient-Centered Trial Design - Julie Gralow
Insight
Jun 8, 2025, 05:54
Nina Niu Sanford Highlighted Role of NCI National Clinical Trials Network in Cancer Research
Blog
Jun 8, 2025, 05:35
Michael Chuong: The IJROBP The Red Journal Special Adaptive Edition (part 1) Is Now In Press
Blog
Jun 8, 2025, 05:28
Omolola Salako Is The Recipient of a 2025 Conference Scholarship - MASCC
Blog
Jun 8, 2025, 00:15
Maryam Lustberg: Free Virtual Nutrition Support for Triple Negative Breast Cancer Patients in the USA
Blog
Jun 7, 2025, 17:41
Praveen Kumar Marimuthu: Best of ASCO 2025 - Common Sense Oncology Version
Blog
Jun 7, 2025, 17:35
Elvina Almuradova: Science Progresses, but If Patients Can’t Access It, We Fail